Ex Vivo Perfusion Treatment of Infection in Human Donor Lungs

American Journal of Transplantation

Volumn 16, Issue 4, 2016, Pages 1229-1237

  Nakajima, D ^a   Cypel, M ^a   Bonato, R ^a   Machuca, T N ^a   Iskender, I ^a   Hashimoto, K ^a   Linacre, V ^a   Chen, M ^a   Coutinho, R ^a   Azad, S ^a   Martinu, T ^a   Waddell, T K ^a   Hwang, D M ^a   Husain, S ^b   Liu, M ^a   Keshavjee, S ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; ENDOTOXIN; INTERLEUKIN 1BETA; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; VASCULOTROPIN; ANTIINFECTIVE AGENT;

ACUTE LUNG INJURY; ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BRONCHOPNEUMONIA; BRONCHOSCOPY; CANDIDA ALBICANS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ENTEROBACTER; ESCHERICHIA COLI; EX VIVO LUNG PERFUSION; EX VIVO STUDY; FEMALE; HAEMOPHILUS INFLUENZAE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG COMPLIANCE; LUNG EDEMA; LUNG FUNCTION; LUNG HEMORRHAGE; LUNG INFECTION; LUNG INJURY; LUNG LAVAGE; LUNG PERFUSION; LUNG TRANSPLANTATION; MALE; ORGAN DONOR; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS ANGINOSUS; SUPPURATION; TRICHOSPORON ASAHII; BACTERIAL LOAD; BRONCHOALVEOLAR LAVAGE FLUID; CASE CONTROL STUDY; COMPARATIVE STUDY; DONOR; DRUG EFFECTS; EXTRACORPOREAL CIRCULATION; FOLLOW UP; LUNG; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PERFUSION; PROCEDURES; PROGNOSIS; STANDARDS; TRANSPLANTATION;

ADULT; ANTI-INFECTIVE AGENTS; BACTERIAL LOAD; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOPNEUMONIA; CASE-CONTROL STUDIES; EXTRACORPOREAL CIRCULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PERFUSION; PROGNOSIS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 84953329303     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13562     Document Type: Article

References (26)

1. Chastre J, Fagon J-Y,. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903.
2. Porzecanski I, Bowton DL., Diagnosis and treatment of ventilator-associated pneumonia. Chest 2006; 130: 597-604.
3. Ruiz I, Gavaldà J, Monforte V, et al., Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant 2006; 6: 178-182.
4. Avlonitis VS, Krause A, Luzzi L, et al., Bacterial colonization of the donor lower airways is a predictor of poor outcome in lung transplantation. Eur J Cardiothorac Surg 2003; 24: 601-607.
5. Bonde PN, Patel ND, Borja MC, et al., Impact of donor lung organisms on post-lung transplant pneumonia. J Heart Lung Transplant 2006; 25: 99-105.
6. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
7. Cypel M, Liu M, Rubacha M, et al., Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1: 4ra 9.
8. Machuca TN, Hsin MK, Ott HC, et al., Injury-specific ex vivo treatment of the donor lung: Pulmonary thrombolysis followed by successful lung transplantation. Am J Respir Crit Care Med 2013; 188: 878-880.
9. Andreasson A, Karamanou DM, Perry JD, et al., The effect of ex vivo lung perfusion on microbial load in human donor lungs. J Heart Lung Transplant 2014; 33: 910-916.
10. Cypel M, Yeung JC, Hirayama S, et al., Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant 2008; 27: 1319-1325.
11. D'Avolio A, Baietto L, De Rosa FG, et al., A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. Ther Drug Monit 2008; 30: 90-94.
12. Meyer KC, Raghu G, Baughman RP, et al., An official American Thoracic Society clinical practice guideline: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185: 1004-1014.
13. Falagas ME, Valkimadi P-E, Huang Y-T, Matthaiou DK, Hsueh P-R,. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: A systematic review. J Antimicrob Chemother 2008; 62: 889-894.
14. Roberts JA, Lipman J., Antibacterial dosing in intensive care: Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755-773.
15. Dorfman MS, Wagner RS, Jamison T, Bell B, Stroman DW., The pharmacodynamic properties of azithromycin in a kinetics-of-kill model and implications for bacterial conjunctivitis treatment. Adv Ther 2008; 25: 208-217.
16. Sevillano D, Alou L, Aguilar L, Echevarría O, Giménez M-J, Prieto J., Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: An in vitro pharmacodynamic simulation. J Antimicrob Chemother 2006; 57: 1128-1133.
17. Birmingham MC, Guarino R, Heller A, et al., Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose. J Antimicrob Chemother 1999; 43(Suppl A): 43-48.
18. Nicolau DP., Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008; 47(Suppl 1): S32 -S40.
19. Gonçalves-Pereira J, Póvoa P., Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams. Crit Care 2011; 15: R206.
20. Edwards JR,. Meropenem: A microbiological overview. J Antimicrob Chemother 1995; 36(Suppl A): 1-17.
21. Rybak M, Lomaestro B, Rotschafer JC, et al., Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
22. Flanagan PG, Jackson SK, Findlay G., Diagnosis of gram negative, ventilator associated pneumonia by assaying endotoxin in bronchial lavage fluid. J Clin Pathol 2001; 54: 107-110.
23. Machuca TN, Cypel M, Yeung JC, et al., Protein expression profiling predicts graft performance in clinical ex vivo lung perfusion. Ann Surg 2015; 261: 591-597.
24. Cypel M, Kaneda H, Yeung JC, et al., Increased levels of interleukin-1β and tumor necrosis factor-α in donor lungs rejected for transplantation. J Hear Lung Transplant 2011; 30: 452-459.
25. Kaneda H, Waddell TK, De Perrot M, et al., Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant 2006; 6: 544-551.
26. Cypel M, Rubacha M, Yeung J, et al., Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant 2009; 9: 2262-2269.